{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:28:13Z","timestamp":1790368093683,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01\u2010HL\u201060587"],"award-info":[{"award-number":["U01\u2010HL\u201060587"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01\u2010HL\u201060606"],"award-info":[{"award-number":["U01\u2010HL\u201060606"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01\u2010HL\u2010089758"],"award-info":[{"award-number":["R01\u2010HL\u2010089758"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01\u2010HL\u2010089758"],"award-info":[{"award-number":["R01\u2010HL\u2010089758"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01\u2010HL\u2010089901"],"award-info":[{"award-number":["R01\u2010HL\u2010089901"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR\u2010063120"],"award-info":[{"award-number":["AR\u2010063120"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care & Research"],"published-print":{"date-parts":[[2018,3]]},"abstract":"Objective<\/jats:title>To assess the efficacy of mycophenolate mofetil (MMF<\/jats:styled-content>) and cyclophosphamide (CYC<\/jats:styled-content>) on modified Rodnan skin score (MRSS<\/jats:styled-content>) in participants enrolled in the Scleroderma Lung Study (SLS<\/jats:styled-content>) I and II<\/jats:styled-content>.<\/jats:p><\/jats:sec>Methods<\/jats:title>SLS<\/jats:styled-content> I participants received daily oral CYC<\/jats:styled-content> or matching placebo for 1 year, whereas SLS II<\/jats:styled-content> participants received daily MMF<\/jats:styled-content> for 2 years or daily oral CYC<\/jats:styled-content> for 1 year followed by placebo for second year. We assessed the impact of MMF<\/jats:styled-content> and CYC<\/jats:styled-content> on the MRSS<\/jats:styled-content> in SLS II<\/jats:styled-content> over a 24\u2010month period. We also compared the change in MRSS<\/jats:styled-content> in patients with diffuse cutaneous systemic sclerosis (dcSS<\/jats:styled-content>c) assigned to CYC<\/jats:styled-content> and MMF<\/jats:styled-content> in SLS II<\/jats:styled-content> and SLS<\/jats:styled-content> I versus placebo in SLS<\/jats:styled-content> I over a 24\u2010month period using a linear mixed model.<\/jats:p><\/jats:sec>Results<\/jats:title>In SLS II<\/jats:styled-content>, the baseline mean \u00b1 SD MRSS<\/jats:styled-content> was 14.0 \u00b1 10.6 units for CYC<\/jats:styled-content> and 15.3 \u00b1 10.4 units for MMF<\/jats:styled-content>; 58.5% were classified as dcSS<\/jats:styled-content>c. CYC<\/jats:styled-content> and MMF<\/jats:styled-content> were associated with statistically significant improvements in MRSS<\/jats:styled-content> from baseline over the period of 24 months in dcSS<\/jats:styled-content>c (P<\/jats:italic> < 0.05 at each time point), but there were no differences between the 2 groups. In the dcSS<\/jats:styled-content>c subgroup, the change in MRSS<\/jats:styled-content> from baseline to all 6\u2010month visits was similar in SLS II<\/jats:styled-content> groups (MMF<\/jats:styled-content>, CYC<\/jats:styled-content>, pooled cohort [MMF<\/jats:styled-content> + CYC<\/jats:styled-content>]) and in the SLS<\/jats:styled-content> I CYC<\/jats:styled-content> group and showed statistically significant improvements compared to SLS<\/jats:styled-content> I placebo at 12, 18, and 24 months (P<\/jats:italic> < 0.05).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>In SLS II<\/jats:styled-content>, MMF<\/jats:styled-content> and CYC<\/jats:styled-content> treatment resulted in improvements in MRSS<\/jats:styled-content> in patients with dcSS<\/jats:styled-content>c over 24 months. In addition, MMF<\/jats:styled-content> and CYC<\/jats:styled-content> treatment resulted in statistically significant improvements in MRSS<\/jats:styled-content> in patients with dcSS<\/jats:styled-content>c when compared with the SLS<\/jats:styled-content> I placebo group.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.23282","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T21:11:25Z","timestamp":1495573885000},"page":"439-444","source":"Crossref","is-referenced-by-count":75,"title":["Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo\u2010Controlled Trials"],"prefix":"10.1002","volume":"70","author":[{"given":"Rajaie","family":"Namas","sequence":"first","affiliation":[{"name":"University of Michigan Scleroderma Program Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Wilhalme","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi\u2010Hong","family":"Tseng","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Roth","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Kafaja","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Volkmann","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Clements","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"University of Michigan Scleroderma Program Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24681"},{"key":"e_1_2_6_3_1","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements P","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.4.364"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1493-4"},{"key":"e_1_2_6_11_1","first-page":"298","article-title":"Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease","volume":"29","author":"Pakas I","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1157-y"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel244"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.142000"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.050187"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0010-5"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu285"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9"}],"container-title":["Arthritis Care & Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.23282","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.23282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:32:24Z","timestamp":1759415544000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.23282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/acr.23282"],"URL":"https:\/\/doi.org\/10.1002\/acr.23282","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]}}}